hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06262958, orgStudyIdInfo id: KUH5703459, briefTitle: Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence in Adolescent, acronym: REAL-SMART, statusModule overallStatus: RECRUITING, startDateStruct date: 2017-08-07, primaryCompletionDateStruct date: 2030-06-01, completionDateStruct date: 2030-06-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Kuopio University Hospital, class: OTHER, descriptionModule briefSummary: ASSIST mini-intervention is applied in an electric form in adolescent outpatients to see if it, conditionsModule conditions: Alcoholism, conditions: Substance Abuse, conditions: Alcohol Dependence, conditions: Alcohol-Related Disorders, conditions: Substance Use Disorders, conditions: Adolescent Behavior, conditions: Adolescent Problem Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Clients are randomized into two groups: 1) those receiving TAU and 2) those receiving a mini-intervention for substance and alcohol use an add-on treatment., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: ASSIST, interventions name: Treatment as usual, outcomesModule primaryOutcomes measure: Decreased consumption of alcohol, tobacco or substances, secondaryOutcomes measure: BDI scores, secondaryOutcomes measure: GAD scores, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 19 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Kuopio University Hospital, status: RECRUITING, city: Kuopio, zip: 70110, country: Finland, contacts name: Sanna Voutilainen, Res. nurse, role: CONTACT, phone: +358447175351, email: sanna.voutilainen@kuh.fi, geoPoint lat: 62.89238, lon: 27.67703, hasResults: False
protocolSection identificationModule nctId: NCT06262945, orgStudyIdInfo id: YDU/2024/120-1808, briefTitle: Comperasion the Postoperative Effect of Low Laser Therapy and Platelet Rich Fibrin on Mandibular Third Molar Surgery., statusModule overallStatus: COMPLETED, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2024-02-06, completionDateStruct date: 2024-02-07, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Beste Erismen, class: OTHER, descriptionModule briefSummary: The aim of this study was investigate the comparison of postoperative effects of low laser treatment and platelet-rich fibrin application on mandibular impacted third molar tooth extraction. The study included a total of 60 patients with impacted mandibular third molar. Patients were evaluated in 4 randomly separated groups. In group 1, PRF was applied to the tooth socket. In group 2, PRF was applied to the tooth socket combined with Low Laser Treatment extraorally to the extraction area for three days within surgery day In group 3, Low Laser Treatment was applied to the extraorally to the extraction area for three days within surgery day. In group 4 (control group), tradional osteomy was made. The outcome variables were pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed based on first, second, third, and seventh days following the operation. All of the 4 groups patients were prescribed an 875/125 mg amoxicillin/clavulanic acid tablet twice daily for five days., conditionsModule conditions: Impacted Third Molar Tooth, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Diagnoses, interventions name: traditional osteotomies, interventions name: platelet rich fibrin, interventions name: Antibiotics, Penicillin, interventions name: low laser therapy, bicure laser, interventions name: Analgesic, outcomesModule primaryOutcomes measure: Visual analogue scale (VAS), primaryOutcomes measure: Visual analogue scale (VAS), primaryOutcomes measure: Visual analogue scale (VAS), primaryOutcomes measure: Visual analogue scale (VAS), primaryOutcomes measure: Trismus, primaryOutcomes measure: Trismus, primaryOutcomes measure: Trismus, primaryOutcomes measure: Trismus, primaryOutcomes measure: Swelling, primaryOutcomes measure: Swelling, primaryOutcomes measure: Swelling, primaryOutcomes measure: Swelling, secondaryOutcomes measure: the number of analgesic tablets, secondaryOutcomes measure: the number of analgesic tablets, secondaryOutcomes measure: the number of analgesic tablets, secondaryOutcomes measure: the number of analgesic tablets, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Near East University, city: Nicosia, state: Lefkosa, zip: 99138, country: Cyprus, geoPoint lat: 35.17531, lon: 33.3642, hasResults: False
protocolSection identificationModule nctId: NCT06262932, orgStudyIdInfo id: RADS regimen, briefTitle: Effectiveness of Repeated Amiodarone Dosing Regimen Versus Standard Dosing Regimen in Atrial Fibrillation Patient With Rapid Ventricular Response, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Police General Hospital, Thailand, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare in atrial fibrillation patient with rapid ventricular response. The main question it aims to answer are Effectiveness of Repeated Amiodarone dosing regimen versus standard dosing regimen in Atrial fibrillation patient with rapid ventricular response Participants will receive Amiodarone iv treatment with different regimen* Repeated dosing regimen* Standard dosing regimen, conditionsModule conditions: Atrial Fibrillation, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Amiodarone, outcomesModule primaryOutcomes measure: Heart rate, secondaryOutcomes measure: Normal sinus rhythm at 24 hours, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Major adverse cardiovascular events, secondaryOutcomes measure: Phlebitis, secondaryOutcomes measure: Changed in heart rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06262919, orgStudyIdInfo id: CDRB436I1401, briefTitle: Special Drug Use-results Surveillance of Tafinlar/Mekinist, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2031-12-31, completionDateStruct date: 2031-12-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Novartis Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture., conditionsModule conditions: BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Tafinlar/Mekinist, outcomesModule primaryOutcomes measure: [Pediatric patients] Number of patients and incidence of adverse events/adverse reactions with respect to skeletal and sexual maturation, primaryOutcomes measure: [Adult patients] overall response rate (ORR), secondaryOutcomes measure: [Pediatric patients] Incidence proportion of ORR, secondaryOutcomes measure: [Pediatric and adult patients] Incidence proportion of PFS, secondaryOutcomes measure: [Pediatric patients] Number of patients with changes in height and body weight and sexual maturation, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 99 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Novartis Investigative Site, status: RECRUITING, city: Kobe, state: Hyogo, zip: 650-0011, country: Japan, geoPoint lat: 34.6913, lon: 135.183, locations facility: Novartis Investigative Site, status: RECRUITING, city: Akita, zip: 010-8543, country: Japan, geoPoint lat: 39.71667, lon: 140.10826, locations facility: Novartis Investigative Site, status: RECRUITING, city: Osaka, zip: 534-0021, country: Japan, geoPoint lat: 34.69374, lon: 135.50218, locations facility: Novartis Investigative Site, status: RECRUITING, city: Osaka, zip: 550-0015, country: Japan, geoPoint lat: 34.69374, lon: 135.50218, hasResults: False
protocolSection identificationModule nctId: NCT06262906, orgStudyIdInfo id: BA-VCAP-01, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06262893, orgStudyIdInfo id: Shoulder nerve blocks, briefTitle: Effect of Dexamethasone Adjuvant in Combined Supraclavicular Block and Suprascapular Block Versus Interscalene Block in Patients Undergoing Shoulder Arthroscopy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: In this study the investigators aim to compare the effect of the suprascapular- supraclavicular nerve block in association with dexamethasone to that of the interscalene brachial plexus block on analgesic effect during arthroscopic shoulder surgery, as postoperative pain scores ,postoperative consumption of analgesic rescue medications and diaphragmatic excursion assessment., conditionsModule conditions: Shoulder Arthroscopy Blocks, conditions: Dexamethasone, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Shoulder arthroscopy blocks, outcomesModule primaryOutcomes measure: Postoperative analgesia by visual analog scale (VAS)., secondaryOutcomes measure: Diaphragmatic excursion, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Assiut University, city: Assiut, country: Egypt, contacts name: Assiut University, role: CONTACT, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06262880, orgStudyIdInfo id: BIO-2305, briefTitle: Dietary Supplementation on Gastrointestinal Barrier Function, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-06, primaryCompletionDateStruct date: 2024-12-20, completionDateStruct date: 2025-02-06, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Brightseed, class: INDUSTRY, descriptionModule briefSummary: The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels on parameters of gastrointestinal (GI) health in otherwise generally healthy adults with risk factors (high BMI and waist circumference) for increased GI permeability. The primary hypothesis is that supplementation with plant derived phenolics will improve gut health compared to placebo., conditionsModule conditions: Intestinal Permeability, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 126, type: ESTIMATED, armsInterventionsModule interventions name: plant derived phenolics, interventions name: Microcrystaline cellulose (MCC), outcomesModule primaryOutcomes measure: 0-2 h urine 13C Mannitol excretion, secondaryOutcomes measure: 2 to 8 h urine 13C Mannitol, secondaryOutcomes measure: 0 to 2 h urine LMR, secondaryOutcomes measure: 2 to 8 h urine LMR, secondaryOutcomes measure: Blood Biomarkers, secondaryOutcomes measure: Blood Biomarkers, secondaryOutcomes measure: Blood Biomarkers, secondaryOutcomes measure: Fecal Biomarkers, secondaryOutcomes measure: Fecal Biomarkers, secondaryOutcomes measure: Inflammatory Biomarkers (Blood), secondaryOutcomes measure: Inflammatory Biomarkers (Blood), secondaryOutcomes measure: Inflammatory Biomarkers (Blood), secondaryOutcomes measure: Inflammatory Biomarkers (Blood), secondaryOutcomes measure: 7-day recall of gastrointestinal symptoms, secondaryOutcomes measure: 7-day recall of gastrointestinal symptoms, secondaryOutcomes measure: Stool frequency, secondaryOutcomes measure: Stool consistency, secondaryOutcomes measure: Body Weight, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Biofortis, status: RECRUITING, city: Addison, state: Illinois, zip: 60101, country: United States, contacts name: Chad Cook, role: CONTACT, geoPoint lat: 41.9317, lon: -87.98896, hasResults: False
protocolSection identificationModule nctId: NCT06262854, orgStudyIdInfo id: AOU Careggi Firenze, briefTitle: Efficacy and Safety of Stimulan® for the Treatment of Diabetic Foot Osteomyelitis. The BIG D-FOOT Study, acronym: BIG D-FOOT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Azienda Ospedaliero-Universitaria Careggi, class: OTHER, descriptionModule briefSummary: This study is designed as a double-blind, placebo-controlled, parallel series randomized trial aimed at verifying the effiicacy and safety of a local calcium-sulphate bio-absorbable antibiotic delivery (tobramicina+vancomicina) versus placebo (calcium-sulphate matrix without antibiotics) in patients with diabetic foot osteomyelitis treated with surgical procedures., conditionsModule conditions: Diabete Mellitus, conditions: Foot Ulcer, conditions: Osteomyelitis - Foot, conditions: Surgical Procedure, Unspecified, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Granules of calcium sulphate with and without antibiotics are identical and undistinguishable., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Calcium-sulphate granules with tobramicina+vancomicina, outcomesModule primaryOutcomes measure: The composite primary endpoint of this study will be the incidence osteomyelitis recurrence or new osteomyelitis in adjacent sites or tissue infection at the site of osteomyelitis., secondaryOutcomes measure: Proportion of healed patients, secondaryOutcomes measure: Proportion of osteomyelitis recurrence, secondaryOutcomes measure: Proportion of post-surgical tissue infection, secondaryOutcomes measure: Proportion of wound recurrence, secondaryOutcomes measure: Proportion of patients undergoing major amputation, secondaryOutcomes measure: Proportion of patients undergoing new surgical intervention, secondaryOutcomes measure: Ulcer time-to-healing, secondaryOutcomes measure: Osteomyelitis time-to-recurrence, secondaryOutcomes measure: Any serious adverse events, secondaryOutcomes measure: Any non serious adverse events, secondaryOutcomes measure: Proportion of post-surgical dehiscence, secondaryOutcomes measure: Direct medical costs, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06262841, orgStudyIdInfo id: Murat Kaan Erdem, briefTitle: Post-Surgical Morbidity and Bone Healing of Impacted Lower Third Molars: Piezosurgery vs. Conventional Instruments, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2023-04-01, completionDateStruct date: 2023-04-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Ankara University, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare piezosurgery and conventional surgery in impacted third molar surgery and to determine its effect on postoperative outcomes and quality of life., conditionsModule conditions: Impacted Third Molar Tooth, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 21, type: ACTUAL, armsInterventionsModule interventions name: Piezosurgery, interventions name: Conventional burs, outcomesModule primaryOutcomes measure: Change in Oral Health-related Quality of Life, secondaryOutcomes measure: Change in pain, secondaryOutcomes measure: Change in Mouth opening, secondaryOutcomes measure: Operation time, secondaryOutcomes measure: Change in facial swelling, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ankara University Faculty of Dentistry, city: Ankara, state: Çankaya, zip: 06510, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06262828, orgStudyIdInfo id: UW 24-064, briefTitle: HEARTWISE - P-CARDIAC for Chinese: Population-based Study, acronym: HEARTWISE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2027-01-31, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: The University of Hong Kong, class: OTHER, descriptionModule briefSummary: Cardiovascular disease (CVD) is one of the prominent diseases that affect many people. One cost-effective solution is to identify people at higher risk of CVD by CVD risk prediction model. China-PAR, TRS-2P, and SMART2 are common risk prediction models for prevention. However, these risk scores were mostly based on the routinely self-check health information and multivariable regression without time-varying consideration. Investigators developed a Machine Learning (ML) based risk prediction model, Personalized CARdiovascular DIsease risk Assessment for Chinese (P-CARDIAC) among a predominantly Chinese population in Hong Kong to estimates the 10 years of secondary recurrent CVD risk for the high-risk individuals. The study objective is to evaluate the accuracy of the P-CARDIAC performance in practice among a large-scale Hong Kong population in medicine specialist outpatient clinic (SOPC) and cardiac clinic. The results will reassure cardiologists that the P-CARDIAC risk score is sensitive to the heart disease symptoms. Investigators anticipate that the results may help to facilitate P-CARDIAC in clinical setting and provide more practical information with the development of P-CARDIAC., conditionsModule conditions: Cardiovascular Diseases, conditions: CVD, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 800, type: ESTIMATED, outcomesModule primaryOutcomes measure: The relationship between P-CARDIAC risk score and heart disease related symptoms, primaryOutcomes measure: P-CARDIAC risk thresholds determination, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: School of Nursing, The University of Hong Kong, city: Hong Kong, country: Hong Kong, contacts name: Sze Ling Celine Chui, PhD, role: CONTACT, phone: (852) 3917 6629, email: cslchui@hku.hk, geoPoint lat: 22.27832, lon: 114.17469, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-10-31, uploadDate: 2024-01-31T01:00, filename: Prot_SAP_000.pdf, size: 294821, hasResults: False
protocolSection identificationModule nctId: NCT06262802, orgStudyIdInfo id: 123123, briefTitle: Volumetric Changes in Large Cystic Lesions Using Active Decompression and Distraction Sugosteogenesis vs Passive Decompression, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Radwa Hydar Ragab, class: OTHER, descriptionModule briefSummary: Null hypothesis active decompression and distraction sugosteogenesis is not faster than passive decompression in volume reduction of large cystic lesions, conditionsModule conditions: Odontogenic Cysts, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Active decompression, outcomesModule primaryOutcomes measure: Volume change, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False